Schulman Associates IRB Establishes Itself in Canada
Cincinnati, OH-Oct. 27, 2009
Schulman Associates IRB (Schulman) has expanded its IRB services into Canada with an office in Toronto because of requests from clients, according to the company. The Schulman Canadian Board’s first official meeting is scheduled for this week.
For North American studies which are conducted in both the U.S. and Canada, Canadian and U.S. Board members will review the research together in order to maintain consistency.
“Our clients have asked us to provide review services in Canada. Now that our Canadian IRB is operational, Schulman can provide the same...review for Canadian research as it has provided in the U.S. for the past 26 years,” said Schulman’s CEO, John Isidor.
Schulman provides clients conducting Canadian studies with access to its WebPortal 2.0 service. WebPortal 2.0 interfaces directly with Schulman’s internal system to provide Sponsors and CROs with real-time updates on review status and timelines.
Early next year, Schulman will launch updated electronic tools to provide clients with greater access to critical review information. Schulman’s existing submission forms have been revised to comply with Canadian regulations and terminology. The revisions are minor and the forms will remain familiar to Schulman clients who have used them for U.S. studies.
French-speaking support is available for Canadian studies. Schulman’s U.S. institutional review board is fully accredited by the Association for Accreditation of Human Research Protection Programs (AAHRPP).
For more information on Schulman call Client Services at 513-761-4100 or visit www.sairb.com.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
